Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

Nature Medicine - Tập 15 Số 3 - Trang 285-292 - 2009
Ronald T. Mitsuyasu1, Thomas C. Merigan2, Andrew Carr3, Jerome A. Zack4, Mark A. Winters2, Cassy Workman5, Mark Bloch6, Jacob Lalezari7, S. Hegewisch Becker8, Lorna Thornton8, Bisher Akil9, Homayoon Khanlou10, Robert Finlayson11, Robert M. McFarlane12, Don Smith13, Roger Garsia14, Dávid Ma3, Matthew Law15, John M. Murray15, Christof von Kalle16, Julie A. Ely17, Sharon M Patino17, Alison E. Knop17, Philip Wong17, Alison V. Todd17, Margaret Haughton17, C.J. Fuery17, Janet L. Macpherson17, Geoff Symonds17, Louise Evans17, Susan M. Pond17, David A. Cooper18
1Center for Clinical AIDS Research and Education, University of California–Los Angeles, 9911 West Pico Boulevard, Suite 980, Los Angeles, 90035, California, USA
2Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Drive, Stanford, 94305, California, USA
3St. Vincent's Hospital, 406 Victoria Road, Darlinghurst, 2010, New South Wales, Australia
4Department of Medicine and Microbiology, University of California–Los Angeles, 405 Hilgard Avenue, Los Angeles, 90095, California, USA
5AIDS Research Initiative, 48 Little Oxford Street, Darlinghurst, 2010, New South Wales, Australia
6Holdsworth House Medical Practice, Suite 3/32a Oxford Street, Darlinghurst, 2010, New South Wales, Australia
7Quest Clinical Research, 2300 Sutter Street, San Francisco, 94115, California, USA
8Pacific Horizon Medical Group, 2351 Clay Street, San Francisco, 94115, California, USA
9Health Innovations Research, 9201 Sunset Bouldevard, Los Angeles, 90069, California, USA
10AIDS Healthcare Foundation Research Center, 6255 West Sunset Boulevard, Los Angeles, 90028, California, USA
11Taylor Square Private Clinic, 393 Bourke Street, Darlinghurst, 2010, New South Wales, Australia
12East Sydney Doctors, 102 Burton Street, Darlinghurst, 2010, New South Wales, Australia
13Albion Street Centre, 150 Albion Street, Darlinghurst, 2010, New South Wales, Australia
14Royal Prince Alfred Hospital, Missenden Road, Camperdown, 2050, New South Wales, Australia
15National Centre in HIV Epidemiology and Clinical Research, 376 Victoria Street
16Cincinnati Children's Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, 45229-3039, Ohio, USA
17Johnson & Johnson Research Proprietary Limited, 1 Central Avenue, Australian Technology Park, Eveleigh, Sydney, 1430, New South Wales, Australia
18Darlinghurst, University of New South Wales, 2010, New South Wales, Australia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Taylor, B.S., Sobieszczyk, M.E., McCutchan, F.E. & Hammer, S.M. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358–1590–1602 (2008).

Watkins, D.I., Burton, D.R., Kallas, E.G., Moore, J.P. & Koff, W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14, 617–621 (2008).

Baltimore, D. Gene therapy. Intracellular immunization. Nature 335, 395–396 (1988).

Amado, R.G. et al. Anti–human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1–infected patients. Hum. Gene Ther. 15, 251–262 (2004).

An, D.S. et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. USA 104, 13110–13115 (2007).

Anderson, J. et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes–CCR5 ribozyme, tat-rev siRNA, and TAR decoy–in SCID-hu mouse-derived T cells. Mol. Ther. 15, 1182–1188 (2007).

Bahner, I. et al. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 67, 3199–3207 (1993).

Cagnon, L. & Rossi, J. Retroviral delivery and anti-HIV testing of hammerhead ribozymes. Methods Mol. Biol. 74, 451–457 (1997).

Dropulic, B., Elkins, D.A., Rossi, J.J. & Sarver, N. Ribozymes: use as anti-HIV therapeutic molecules. Antisense Res. Dev. 3, 87–94 (1993).

Fanning, G., Amado, R. & Symonds, G. Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen. J. Gene Med. 5, 645–653 (2003).

Kohn, D.B. Gene therapy using hematopoietic stem cells. Curr. Opin. Mol. Ther. 1, 437–442 (1999).

Kohn, D.B. et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94, 368–371 (1999).

Li, M., Li, H. & Rossi, J.J. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann. NY Acad. Sci. 1082, 172–179 (2006).

Lo, A.S., Zhu, Q. & Marasco, W.A. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb. Exp. Pharmacol. 181, 343–373 (2008).

Marasco, W.A., LaVecchio, J. & Winkler, A. Human anti–HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J. Immunol. Methods 231, 223–238 (1999).

Mautino, M.R. & Morgan, R.A. Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. Hum. Gene Ther. 11, 2025–2037 (2000).

Morgan, R.A. et al. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum. Gene Ther. 16, 1065–1074 (2005).

Morris, K.V. & Rossi, J.J. Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum. Gene Ther. 17, 479–486 (2006).

Rossi, J.J. The application of ribozymes to HIV infection. Curr. Opin. Mol. Ther. 1, 316–322 (1999).

Strayer, D.S. et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol. Ther. 11, 823–842 (2005).

Taylor, J.A. et al. Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication. Mol. Ther. 16, 46–51 (2008).

von Laer, D., Hasselmann, S. & Hasselmann, K. Gene therapy for HIV infection: what does it need to make it work? J. Gene Med. 8, 658–667 (2006).

Zahn, R.C. et al. Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther. 15, 1210–1222 (2008).

Sarver, N. et al. Ribozymes as potential anti–HIV-1 therapeutic agents. Science 247, 1222–1225 (1990).

Schambach, A. et al. Towards hematopoietic stem cell–mediated protection against infection with human immunodeficiency virus. Gene Ther. 13, 1037–1047 (2006).

Rossi, J.J., June, C.H. & Kohn, D.B. Genetic therapies against HIV. Nat. Biotechnol. 25, 1444–1454 (2007).

Macpherson, J.L., Ely, J.A., Sun, L.Q. & Symonds, G.P. Ribozymes in gene therapy of HIV-1. Front. Biosci. 4, D497–D505 (1999).

Levine, B.L. et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).

Macpherson, J.L. et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T lymphocytes in HIV-infected patients. J. Gene Med. 7, 552–564 (2005).

Podsakoff, G.M. et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol. Ther. 12, 77–86 (2005).

Sun, L.Q., Ely, J.A., Gerlach, W. & Symonds, G. Anti-HIV ribozymes. Mol. Biotechnol. 7, 241–251 (1997).

Sun, L.Q., Wang, L., Gerlach, W.L. & Symonds, G. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res. 23, 2909–2913 (1995).

Sun, L.Q. et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc. Natl. Acad. Sci. USA 92, 7272–7276 (1995).

Rossi, J.J. Ribozyme therapy for HIV infection. Adv. Drug Deliv. Rev. 44, 71–78 (2000).

Wang, L. et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum. Gene Ther. 9, 1283–1291 (1998).

Center for Biologics Evaluation and Research. Guidance for Industry: Gene Therapy Clinical Trials—Observing Subjects for Delayed Adverse Events. (US Department of Health and Human Services, Rockville, Maryland, 2006).

Center for Biologics Evaluation and Research. Guidance for Industry: Supplemental Guidances on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors. (US Department of Health and Human Services, Rockville, Maryland, 2006).

Cavallaro, A.M. et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 25, 85–89 (2000).

Nicolini, F.E. et al. Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion. Exp. Hematol. 32, 1033–1039 (2004).

Novotny, J. et al. Sustained decrease of peripheral lymphocytes after allogeneic blood stem cell aphereses. Br. J. Haematol. 100, 695–697 (1998).

Malech, H.L. et al. Prolonged production of NADPH oxidase–corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 94, 12133–12138 (1997).

Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002).

Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003).

Ott, M.G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1–EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401–409 (2006).

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283–2296 (2006).

Schmidt, M. et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods 4, 1051–1057 (2007).

Thông tin
Thông tin xuất bản

Nature Medicine

Tập 15 Số 3

285-292

Thông tin tác giả